Cargando…

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity

BACKGROUND: The management of ultracentral thoracic tumors with ablative dose of radiotherapy remains challenging given proximity to critical central structures. We report patient outcomes, toxicity, and dosimetry for ultracentrally located tumors with hypofractionated stereotactic body radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rock, Crosby, Sood, Sumit, Cao, Ying, Shelton, Shary, Chen, Ronald C., Wang, Fen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394937/ https://www.ncbi.nlm.nih.gov/pubmed/37533092 http://dx.doi.org/10.1186/s13014-023-02298-1

Ejemplares similares

Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors
por: Owen, Dawn, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
por: Yang, Dan, et al.
Publicado: (2020)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
por: Sandoval, Maria L., et al.
Publicado: (2023)

Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors
por: Zhao, Yizhou, et al.
Publicado: (2020)

An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
por: Zarębska, Izabela, et al.
Publicado: (2023)

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
por: Regnery, Sebastian, et al.
Publicado: (2020)

External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
por: Chen, Ishita, et al.
Publicado: (2022)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry
por: McDonald, Andrew M., et al.
Publicado: (2012)

Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis
por: Rim, Chai Hong, et al.
Publicado: (2020)

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)
por: Regnery, Sebastian, et al.
Publicado: (2022)

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
por: Jiang, Huayong, et al.
Publicado: (2021)

Hypofractionated stereotactic radiotherapy for large arteriovenous malformations
por: Wang, Huan-Chih, et al.
Publicado: (2012)

Hypofractionated radiotherapy in postmastectomy locally advanced breast cancer: an interim report on acute toxicities and dosimetry
por: Jamora, Kurl, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases
por: Księżniak-Baran, Dorota, et al.
Publicado: (2015)

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: Toxicity and quality of life assessment
por: Rucinska, Monika, et al.
Publicado: (2016)

Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
por: Hirata, Masanori, et al.
Publicado: (2022)

Intracranial chordoma: radiosurgery, hypofractionated stereotactic radiotherapy and treatment outcomes
por: Napieralska, Aleksandra, et al.
Publicado: (2021)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
por: Gutschenritter, Tyler, et al.
Publicado: (2020)

Normal tissue toxicity after small field hypofractionated stereotactic body radiation
por: Milano, Michael T, et al.
Publicado: (2008)

Hypofractionation Radiotherapy vs. Conventional Fractionation for Breast Cancer: A Comparative Review of Toxicity
por: Youssef, Ashraf, et al.
Publicado: (2018)

Correction: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases
por: Hirata, Masanori, et al.
Publicado: (2023)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control
por: Meniai-Merzouki, F., et al.
Publicado: (2018)

Reproducibility and geometric accuracy of the fixster system during hypofractionated stereotactic radiotherapy
por: Lindvall, Peter, et al.
Publicado: (2008)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
por: Jiang, Xue-song, et al.
Publicado: (2012)

Cone-beam computed tomography in hypofractionated stereotactic radiotherapy for brain metastases
por: Ingrosso, Gianluca, et al.
Publicado: (2012)

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis
por: Kim, Dong-Yun, et al.
Publicado: (2020)

Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases
por: Xie, Xue-Yi, et al.
Publicado: (2022)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Hypofractionated stereotactic radiotherapy for large or involving critical organs cerebral arteriovenous malformations
por: Blamek, Sławomir, et al.
Publicado: (2013)

Successful Treatment of Infantile Fibrosarcoma Spinal Metastasis by Chemotherapy and Stereotactic Hypofractionated Radiotherapy
por: Lo, Cheng-Hsiang, et al.
Publicado: (2013)

Retrospective analysis of hypofractionated stereotactic radiotherapy for tumors larger than 2 cm
por: Koide, Yutaro, et al.
Publicado: (2019)

Promising Outcomes in Acromegaly Patients Receiving CyberKnife Stereotactic Hypofractionated Radiotherapy
por: Meral, Rasim, et al.
Publicado: (2023)

Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial
por: Henke, Lauren E., et al.
Publicado: (2018)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy
por: Kamogawa, Misaki, et al.
Publicado: (2022)

Stereotactic linac radiosurgery and hypofractionated stereotactic radiotherapy for pediatric arteriovenous malformations of the brain: experiences of a single institution
por: Blamek, Sławomir, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_q9sm55uls2akhh9biqjllllf6k